Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS32015 Bridging Therapy for RRMM
NCT07185477Phase 1Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2025
- Primary completion
- May 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of QLS32015 in multiple myeloma (MM) and Plasma cell leukemia (pPCL), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
QLS32015
03
Conditions
multiple myeloma (MM)Plasma cell leukemia (pPCL)
Beyond the preview
Go deeper on NCT07185477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07185477.